Two of the metalloprotease inhibitors tested in our study, DPC‐333 and apratastat, were developed to block ADAM17‐mediated TNFα shedding and previously entered phase 2 clinical trials for the treatment of the inflammatory joint disorder rheumatoid arthritis. Here, ADAM17 is linked to rheumatoid arthritis.